|Awarded On||August 20, 2014|
|Title||Synthetic Protein Degradation Agents To Clear Oncogenic Proteins From Cells|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Andreas Matouschek|
|Cancer Sites||All Sites|
A hallmark of cancer is the presence of proteins that inappropriately signal cells to grow and to divide. We are developing a strategy to purge such oncogenic proteins from cells by taking advantage of the cells’ own protein removal system. Cancer cells can be addicted to oncogenic proteins and die when they no longer receive the growth stimulus from these proteins. For example, the drug Gleevec kills cancer cells by inhibiting the oncogenic protein Bcr-Abl from sending its growth signal. Thus, clearing oncogenic proteins from cells could be a novel strategy for molecularly targeted therapeutics. Cells constantly remove proteins that are unwanted and much of this protein removal occurs by th...